These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 25965589)

  • 21. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gastrointestinal bleeding after treatment with ticagrelor].
    Hauge J; Kragh R; Poulsen BK
    Ugeskr Laeger; 2013 Mar; 175(11):737-8. PubMed ID: 23480887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports.
    DiNicolantonio JJ; Serebruany VL
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):5-9. PubMed ID: 23393061
    [No Abstract]   [Full Text] [Related]  

  • 24. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
    Serebruany VL; Sibbing D; DiNicolantonio JJ
    Cardiology; 2014; 127(1):20-4. PubMed ID: 24192670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
    May CH; Lincoff AM
    Expert Opin Drug Saf; 2012 Nov; 11(6):959-67. PubMed ID: 22950441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
    Steiner JB; Wu Z; Ren J
    Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel-associated acute generalized exanthematous pustulosis.
    Ellerbroek JC; Cleveland MG
    Cutis; 2011 Apr; 87(4):181-5. PubMed ID: 21644491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.
    Deharo P; Bassez C; Bonnet G; Pankert M; Quilici J; Lambert M; Verdier V; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2013 Dec; 170(2):e21-2. PubMed ID: 24231059
    [No Abstract]   [Full Text] [Related]  

  • 31. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn.
    Sánchez-Galian MJ; Flores-Blanco PJ; López-Cuenca A; Gómez-Molina M; Guerrero-Pérez E; Cambronero-Sánchez F; Sánchez-Martínez M; Valdés M; Manzano-Fernández S
    Int J Cardiol; 2015; 187():517-8. PubMed ID: 25846663
    [No Abstract]   [Full Text] [Related]  

  • 33. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
    Gaglia MA; Waksman R
    Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
    Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
    Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
    Cheng VE; Oppermen A; Natarajan D; Haikerwal D; Pereira J
    Heart Lung Circ; 2014 Apr; 23(4):e115-7. PubMed ID: 24480082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
    Alexopoulos D; Xanthopoulou I; Moulias A; Lekakis J
    J Am Coll Cardiol; 2016 Sep; 68(11):1223-1232. PubMed ID: 27609686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
    Manchette AM; Drucker AG; Januzzi JL
    Pharmacotherapy; 2014 Aug; 34(8):e152-6. PubMed ID: 24898185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.